RxDoctor Payments Data

Rita Sharma, MD

Internal Medicine · Southfield, MINPI 1205817038

Payments from drug & device makers

$8,681in general payments, 2019–2025

Across 487 payments — averaging $17.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Lilly USA, LLC$1K
  • Novo Nordisk$914
  • Boehringer Ingelheim$625
  • Amgen$426
  • Madrigal Pharmaceuticals$386
  • plus $3K from 40 others

What the payments were for

  • Food & beverage$8,681100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,681 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$68,145
Medicare patients
69
Services billed
1,086

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban48$45,754
TrulicityDulaglutide31$41,954
JardianceEmpagliflozin20$28,129
FarxigaDapagliflozin Propanediol32$24,222
OzempicSemaglutide14$12,739
VyvanseLisdexamfetamine Dimesylate11$12,609
JanuviaSitagliptin Phosphate12$10,367
Lantus SolostarInsulin Glargine,hum.Rec.Anlog30$2,991
Raloxifene Hcl51$2,716
Atorvastatin Calcium179$1,930
Losartan Potassium130$1,676
Tolterodine Tartrate ErTolterodine Tartrate11$1,619
Amlodipine Besylate230$1,527
Metoprolol Succinate76$1,308
Metformin Hcl108$1,122

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$222$45,75448 claims
Lilly USA, LLCTrulicity$1,035$41,95431 claims
Boehringer IngelheimJardiance$625$28,12920 claims
AstraZenecaFarxiga$2,047$24,22232 claims
Novo NordiskOzempic$914$12,73914 claims
Takeda Pharmaceuticals U.S.A., Inc.Vyvanse$92$12,60911 claims
MerckJanuvia$222$10,36712 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$57$75478 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Southfield

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →